The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). Issue 2 (21st February 2019)

• Record Type: Journal Article
• Authors: Pérol, David; Robain, Mathieu; Arveux, Patrick; Mathoulin-Pélissier, Simone; Chamorey, Emmanuel; Asselain, Bernard; Berchery, Delphine; Gourgou, Sophie; Breton, Mathias; Delaine-Clisant, Stéphanie; Mons, Muriel; Diéras, Véronique; Carton, Matthieu; Guizard, Anne-Valérie; Laborde, Lilian; Laurent, Carine; Loeb, Agnès; Mouret-Reynier, Marie-Ange; Parent, Damien; Perrocheau, Geneviève; Campion, Loïc; Velten, Michel; Cailliot, Christian; Ezzalfani, Monia; Simon, Gaëtane
• Is Part Of: BMJ open. Volume 9:Issue 2(2019)
• Publication Date: 2019-02-21
• Subjects: real-world data -- data platform -- epidemiology -- patient medical record -- quality control -- metastatic breast cancer; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-023568
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Purpose: The currently ongoing Epidemiological Strategy and Medical Economics (ESME) research programme aims at centralising real-life data on oncology care for epidemiological research purposes. We draw on results from the metastatic breast cancer (MBC) cohort to illustrate the methodology used for data collection in the ESME research programme. Participants: All consecutive ≥18 years patients with MBC treatment initiated between 2008 and 2014 in one of the 18 French Comprehensive Cancer Centres were selected. Diagnostic, therapeutic and follow-up data (demographics, primary tumour, metastatic disease, treatment patterns and vital status) were collected through the course of the disease. Data collection is updated annually. Finding to date: With a recruitment target of 30 000 patients with MBC by 2019, we currently screened a total of 45 329 patients, and >16 700 patients with a metastatic disease treatment initiated after 2008 have been selected. 20.7% of patients had an hormone receptor (HR)-negative MBC, 73.7% had a HER2-negative MBC and 13.9% were classified as triple-negative BC (ie, HER2 and HR status both negative). Median follow-up duration from MBC diagnosis was 48.55 months for the whole cohort. Future plans: These real-world data will help standardise the management of MBC and improve patient care. A dozen of ancillary research projects have been conducted and some of them are already accepted for publication or ready to be issued. The ESME research programme is expanding to ovarian cancer and advanced/metastatic lung cancer. Our ultimate goal is to achieve a continuous link to the data of the cohort to the French national Health Data System for centralising data on healthcare reimbursement (drugs, medical procedures), inpatient/outpatient stays and visits in primary/secondary care settings. Trial registration number: NCT03275311 ; Pre-results.